Truvelog Mix 30

On 25 January 2024, the European Commission withdrew the marketing authorisation for Truvelog Mix 30 (insulin aspart) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Winthrop Industrie, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Truvelog Mix 30 was granted marketing authorisation in the EU on 25 April 2022 for the treatment of diabetes mellitus. The European Public Assessment Report (EPAR) for Truvelog Mix 30 will be updated to indicate that the marketing authorisation is no longer valid.